Claims for Patent: 9,067,992

✉ Email this page to a colleague

Summary for Patent: 9,067,992

Title:	Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Abstract:	The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF.alpha. antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Inventor(s):	Hoffman; Rebecca S. (Wilmette, IL), Weinberg; Mark (Northbrook, IL)
Assignee:	AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:	14/563,056
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,067,992
Patent Claims:	1. A method of treatment of moderate to severe active psoriatic arthritis in adult patients, wherein each said patient has .gtoreq.3 swollen and .gtoreq.3 tender joints prior to the treatment and has failed NSAID therapy, comprising subcutaneously administering to each said patient 40 mg of adalimumab every other week, wherein 23% of said patients achieve 70% reduction in American College of Rheumatology (ACR) score at week 24 of the treatment. 2. A method for reducing or inhibiting symptoms in a patient with psoriatic arthritis, comprising subcutaneously administering to said patient 40 mg of adalimumab every other week. 3. The method of claim 2, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 4. The method of claim 3, wherein said 40 mg adalimumab is formulated at a concentration of 50 mg/ml. 5. The method of claim 2, wherein the patient achieves at least a 50% reduction in ACR score at week 24 of the treatment. 6. The method of claim 5, wherein the patient achieves at least a 70% reduction in ACR score at week 24 of the treatment. 7. The method of claim 2, wherein said symptoms are progression of structural damage assessed by radiograph. 8. The method of claim 7, wherein said 40 mg adalimumab is comprised in a pre-filled syringe for subcutaneous injection. 9. The method of claim 8, wherein said 40 mg adalimumab is formulated at a concentration of 50 mg/ml.

Details for Patent 9,067,992

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	9,067,992	2021-03-07
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	9,067,992	2021-03-07
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	9,067,992	2021-03-07
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	9,067,992	2021-03-07
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	November 23, 2015	9,067,992	2021-03-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,067,992

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
South Africa	201006269	⤷ Subscribe
South Africa	200810349	⤷ Subscribe
South Africa	200608097	⤷ Subscribe
South Africa	200502983	⤷ Subscribe
South Africa	200500068	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.